Sorafenib in Metastatic Papillary Thyroid Carcinoma with <i>BRAF K601E</i> Mutation on Liquid Biopsy: A Case Report and Literature Review
Differentiated thyroid cancer (DTC) includes papillary and follicular carcinomas and is the most common type of thyroid cancer. The incidence of this cancer has increased in the last few years, and even if its prognosis is generally good for a subset of patients that does not respond to radioactive...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-05-01
|
| Series: | Medicina |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1648-9144/58/5/666 |
| _version_ | 1797498055398785024 |
|---|---|
| author | Marianna Caterino Mario Pirozzi Sergio Facchini Alessia Zotta Antonello Sica Giorgio Lo Giudice Raffaele Rauso Elisa Varriale Fortunato Ciardiello Morena Fasano |
| author_facet | Marianna Caterino Mario Pirozzi Sergio Facchini Alessia Zotta Antonello Sica Giorgio Lo Giudice Raffaele Rauso Elisa Varriale Fortunato Ciardiello Morena Fasano |
| author_sort | Marianna Caterino |
| collection | DOAJ |
| description | Differentiated thyroid cancer (DTC) includes papillary and follicular carcinomas and is the most common type of thyroid cancer. The incidence of this cancer has increased in the last few years, and even if its prognosis is generally good for a subset of patients that does not respond to radioactive iodine (RAI) therapy, the prognosis is much worse: the median overall survival (OS) from discovery of metastasis is 3–5 years and the 10-year survival rate is only 10%. Several mutations, including RAS or RET, as well as BRAF signaling, are associated with thyroid cancer. Liquid biopsy may be useful in selected patient to identify genomic alterations and thus allowing for a precision medicine approach with target therapy. Sorafenib, an oral multi-kinase inhibitor, can be used in the treatment of DTC. Case presentation: A 77 years old. man with diagnosis of metastatic DTC and evidence of presence of mutation of BRAF K601E on liquid biopsy was treated with sorafenib, showing a good response to the treatment and an improvement in the quality of life (QoL). Currently, this patient is still on treatment with sorafenib, gaining control of a multi-metastatic disease, generally characterized by a very poor prognosis. In conclusion, sorafenib has an active role in the treatment of DTC. It also has been considered the standard of care for patients with advanced unresectable hepatocellular carcinoma (HCC) and renal cell carcinoma (RCC). In our case we observe the efficacy of using sorafenib in Papillary thyroid carcinoma (PTC) such as confirming both stable disease (SD) in the CT scan as clinical benefit with an increase in QoL. Therefore, use of sorafenib remains an important treatment option, even in case of BRAF mutation, despite a rapidly evolving treatment landscape. It also seems important to perform liquid biopsies, especially in patients in whom it is not possible to repeat a new tissue biopsy. Ongoing clinical trials continue to evaluate sorafenib in different settings, and in combination with other therapies in DTC and HCC. |
| first_indexed | 2024-03-10T03:27:57Z |
| format | Article |
| id | doaj.art-6c98737dae3e424a9f52fba880e9b29a |
| institution | Directory Open Access Journal |
| issn | 1010-660X 1648-9144 |
| language | English |
| last_indexed | 2024-03-10T03:27:57Z |
| publishDate | 2022-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Medicina |
| spelling | doaj.art-6c98737dae3e424a9f52fba880e9b29a2023-11-23T12:04:13ZengMDPI AGMedicina1010-660X1648-91442022-05-0158566610.3390/medicina58050666Sorafenib in Metastatic Papillary Thyroid Carcinoma with <i>BRAF K601E</i> Mutation on Liquid Biopsy: A Case Report and Literature ReviewMarianna Caterino0Mario Pirozzi1Sergio Facchini2Alessia Zotta3Antonello Sica4Giorgio Lo Giudice5Raffaele Rauso6Elisa Varriale7Fortunato Ciardiello8Morena Fasano9Division of Oncology, Department of Precision Medicine, University of Campania, 80010 Naples, ItalyDivision of Oncology, Department of Precision Medicine, University of Campania, 80010 Naples, ItalyDivision of Oncology, Department of Precision Medicine, University of Campania, 80010 Naples, ItalyDivision of Oncology, Department of Precision Medicine, University of Campania, 80010 Naples, ItalyDivision of Oncology, Department of Precision Medicine, University of Campania, 80010 Naples, ItalyMaxillofacial Surgery Unit, Department of Neurosciences, Reproductive and Odontostomatological Sciences, University of Naples “Federico II”, Via Pansini, 5, 80131 Naples, ItalyHead and Neck Unit, Clinica Cobellis, 84078 Vallo della Lucania, ItalyDivision of Oncology, Fatebenefratelli Hospital, 80123 Naples, ItalyDivision of Oncology, Department of Precision Medicine, University of Campania, 80010 Naples, ItalyDivision of Oncology, Department of Precision Medicine, University of Campania, 80010 Naples, ItalyDifferentiated thyroid cancer (DTC) includes papillary and follicular carcinomas and is the most common type of thyroid cancer. The incidence of this cancer has increased in the last few years, and even if its prognosis is generally good for a subset of patients that does not respond to radioactive iodine (RAI) therapy, the prognosis is much worse: the median overall survival (OS) from discovery of metastasis is 3–5 years and the 10-year survival rate is only 10%. Several mutations, including RAS or RET, as well as BRAF signaling, are associated with thyroid cancer. Liquid biopsy may be useful in selected patient to identify genomic alterations and thus allowing for a precision medicine approach with target therapy. Sorafenib, an oral multi-kinase inhibitor, can be used in the treatment of DTC. Case presentation: A 77 years old. man with diagnosis of metastatic DTC and evidence of presence of mutation of BRAF K601E on liquid biopsy was treated with sorafenib, showing a good response to the treatment and an improvement in the quality of life (QoL). Currently, this patient is still on treatment with sorafenib, gaining control of a multi-metastatic disease, generally characterized by a very poor prognosis. In conclusion, sorafenib has an active role in the treatment of DTC. It also has been considered the standard of care for patients with advanced unresectable hepatocellular carcinoma (HCC) and renal cell carcinoma (RCC). In our case we observe the efficacy of using sorafenib in Papillary thyroid carcinoma (PTC) such as confirming both stable disease (SD) in the CT scan as clinical benefit with an increase in QoL. Therefore, use of sorafenib remains an important treatment option, even in case of BRAF mutation, despite a rapidly evolving treatment landscape. It also seems important to perform liquid biopsies, especially in patients in whom it is not possible to repeat a new tissue biopsy. Ongoing clinical trials continue to evaluate sorafenib in different settings, and in combination with other therapies in DTC and HCC.https://www.mdpi.com/1648-9144/58/5/666differential thyroid cancer (DTC)TKIsorafenib |
| spellingShingle | Marianna Caterino Mario Pirozzi Sergio Facchini Alessia Zotta Antonello Sica Giorgio Lo Giudice Raffaele Rauso Elisa Varriale Fortunato Ciardiello Morena Fasano Sorafenib in Metastatic Papillary Thyroid Carcinoma with <i>BRAF K601E</i> Mutation on Liquid Biopsy: A Case Report and Literature Review Medicina differential thyroid cancer (DTC) TKI sorafenib |
| title | Sorafenib in Metastatic Papillary Thyroid Carcinoma with <i>BRAF K601E</i> Mutation on Liquid Biopsy: A Case Report and Literature Review |
| title_full | Sorafenib in Metastatic Papillary Thyroid Carcinoma with <i>BRAF K601E</i> Mutation on Liquid Biopsy: A Case Report and Literature Review |
| title_fullStr | Sorafenib in Metastatic Papillary Thyroid Carcinoma with <i>BRAF K601E</i> Mutation on Liquid Biopsy: A Case Report and Literature Review |
| title_full_unstemmed | Sorafenib in Metastatic Papillary Thyroid Carcinoma with <i>BRAF K601E</i> Mutation on Liquid Biopsy: A Case Report and Literature Review |
| title_short | Sorafenib in Metastatic Papillary Thyroid Carcinoma with <i>BRAF K601E</i> Mutation on Liquid Biopsy: A Case Report and Literature Review |
| title_sort | sorafenib in metastatic papillary thyroid carcinoma with i braf k601e i mutation on liquid biopsy a case report and literature review |
| topic | differential thyroid cancer (DTC) TKI sorafenib |
| url | https://www.mdpi.com/1648-9144/58/5/666 |
| work_keys_str_mv | AT mariannacaterino sorafenibinmetastaticpapillarythyroidcarcinomawithibrafk601eimutationonliquidbiopsyacasereportandliteraturereview AT mariopirozzi sorafenibinmetastaticpapillarythyroidcarcinomawithibrafk601eimutationonliquidbiopsyacasereportandliteraturereview AT sergiofacchini sorafenibinmetastaticpapillarythyroidcarcinomawithibrafk601eimutationonliquidbiopsyacasereportandliteraturereview AT alessiazotta sorafenibinmetastaticpapillarythyroidcarcinomawithibrafk601eimutationonliquidbiopsyacasereportandliteraturereview AT antonellosica sorafenibinmetastaticpapillarythyroidcarcinomawithibrafk601eimutationonliquidbiopsyacasereportandliteraturereview AT giorgiologiudice sorafenibinmetastaticpapillarythyroidcarcinomawithibrafk601eimutationonliquidbiopsyacasereportandliteraturereview AT raffaelerauso sorafenibinmetastaticpapillarythyroidcarcinomawithibrafk601eimutationonliquidbiopsyacasereportandliteraturereview AT elisavarriale sorafenibinmetastaticpapillarythyroidcarcinomawithibrafk601eimutationonliquidbiopsyacasereportandliteraturereview AT fortunatociardiello sorafenibinmetastaticpapillarythyroidcarcinomawithibrafk601eimutationonliquidbiopsyacasereportandliteraturereview AT morenafasano sorafenibinmetastaticpapillarythyroidcarcinomawithibrafk601eimutationonliquidbiopsyacasereportandliteraturereview |